[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644499":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":26,"locations":32,"responsibleParty":47,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":9,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":77,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"RayzeBio, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Imaging Study of a CAIX Binder in Metastatic Clear Cell RCC.","EXPERIMENTAL",null,[13],"Diagnostic Test: RYZ512",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIAGNOSTIC_TEST","RYZ512","Imaging Agent",[9],[21,24],{"name":22,"affiliation":5,"role":23},"Freddy Escorcia, MD, PhD","STUDY_DIRECTOR",{"name":25,"affiliation":5,"role":23},"Heying Duan, MD",[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"RayzeBio Clinical Trials","CONTACT","(619) 657-0057","clinicaltrials@rayzebio.com",[33],{"facility":34,"status":11,"city":35,"state":11,"zip":11,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Research Facility","Christchurch","New Zealand","NZ",{"type":39,"coordinates":40},"Point",[41,42],172.63333,-43.53333,{"lat":42,"lon":41},[45],{"name":46,"role":29,"phone":11,"phoneExt":11,"email":11},"Site Contact",{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100644499","early-phase-1-imaging-study-of-a-caix-binder-in-metastatic-clear-cell-rcc-100644499",false,"NCT07671417","A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of a Carbonic Anhydrase IX (CAIX) Binder in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).","Inclusion Criteria:\n\n* At least 18 years old at the time of signing the informed consent form (ICF).\n* Biopsy proven metastatic clear cell renal cell carcinoma (RCC)\n\nExclusion Criteria:\n\n* Subjects taking below mentioned medications that cannot be stopped 5 half-lives prior to RYZ512 administration and cannot be restarted until all study-related imaging is completed: Anticonvulsants, Antipsychotics, Carbonic Anhydrase inhibitors, COX-2 Inhibitors, Sulfatase Inhibitors, Sulfonamides\n* Women of Childbearing Potential that are pregnant or breastfeeding.\n\nNote: Additional criteria may apply and will be assessed by the study site","ALL","18 Years",{"count":58,"type":59},10,"ESTIMATED","INTERVENTIONAL",[62],"EARLY_PHASE1","This imaging study aims to assess the feasibility, biodistribution, and dosimetry of a novel Carbonic Anhydrase IX (CAIX) Binder in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).",[65],"Metastatic Clear Cell Renal Cell Carcinoma",[67,68,69,70,71,72,73,74,75,76,18],"RCC","Metastatic RCC","Metastatic Clear Cell Renal Cancer","CAIX","CA9","RayzeBio","Rayze","BMS","Bristol Myers Squibb","RPT","NOT_YET_RECRUITING","2026-06-22",{"date":80,"type":81},"2026-06-26","ACTUAL",{"date":83,"type":59},"2026-06",{"date":85,"type":59},"2027-01",{"name":5,"class":6},1]